Key Takeaways & Executive Findings
- •• PIP2 and PIPKI regulate the membrane translocation of Smurf1, a key E3 ubiquitin ligase. • The C2 domain of Smurf1 directly binds to PIP2, which is essential for its membrane recruitment and E3 ligase activity. • The PIPKI-PIP2-Smurf1 signaling axis is critical for cell migration, offering a potential therapeutic target in cancer. • This study provides mechanistic insight into how membrane localization controls Smurf1 function, with implications for understanding cell polarity and migration.
Abstract
Smurf1 is a member of the Nedd4 family of E3 ubiquitin ligases. Numerous lines of evidence indicate that the membrane localization of Smurf1 is essential for its activity. However, the underlying mechanisms that regulate the membrane localization of Smurf1 remain unclear. Type I phosphatidylinositol phosphate kinase (PIPKI) is a phosphatidylinositol kinase that generates phosphatidylinositol 4,5-bisphosphate (PIP2), which is located in the plasma membrane and regulates cellular processes, including ion channel activity and cell migration. In this study, we show that PIP2 and PIPKI regulate the membrane translocation of Smurf1. Importantly, the recruitment of Smurf1 to the cell membrane through the association of its C2 domain with PIPKI-produced PIP2 is essential for Smurf1-mediated E3 ligase activity and cell migration. Therefore, we identify a PIPKI-PIP2-Smurf1 signaling axis that regulates cell migration.
1. Introduction
Smurf1 is homologous to the E6AP carboxyl terminus (HECT) E3 ubiquitin ligase and plays critical roles in cell polarity, cell migration, and development via targeting various substrates, such as Smad, RhoA, and Talin [1–5]. Smurf1 negatively regulates osteoblast activity and the BMP response by ubiquitinating and degrading MEKK2, thereby preventing age-dependent bone mass accumulation through JNK signaling activation [6,7]. Smurf1 contains a C2 domain, a WW domain, and a HECT domain [8,9]. The C2 domain of Smurf1 is involved in direct binding to some substrates, such as RhoA and hPEM-2 [5,10,11]. In addition, the C2 domain of Smurf1 is required for membrane localization [2,12]. The membrane localization of Smurf1 is essential for its E3 ubiquitin ligase activity and cell migration [2,13]. However, the underlying mechanisms that regulate the membrane localization of Smurf1 and its functions in cell migration remain elusive.
Phosphatidylinositol 4,5-bisphosphate (PIP2) has been reported to be involved in diverse cellular processes, including focal adhesion formation, proliferation, and migration, through the recruitment and/or regulation of cytosolic proteins [14–16]. Type I phosphatidylinositol phosphate kinase (PIPKI) is a member of the phosphatidylinositol kinase family that generates PIP2 through the phosphorylation of phosphotidylinositol 4-phosphate (PI4P) at the D-5 position of the inositol ring [14,17,18]. PIPKI plays an important role in the polarity and migration of both adherent cells and leukocytes [19]. The binding of Talin re-localizes PIPKIγi2 to focal adhesions and regulates localized PIP2 levels and cell migration [17,20]. Our recent results revealed that PIPKI is a substrate of the E3 ubiquitin ligase Smurf1 and that the PKA-Smurf1-PIPKI signaling axis plays an important role in lung cancer cell growth [9]. Furthermore, we were interested in whether PIPKI regulates Smurf1-mediated activity and function.
In this study, we revealed that binding of PIP2 to the C2 domain of Smurf1 is essential for Smurf1 membrane recruitment. PIP2 and PIPKI are required for the E3 ligase activity and cell migration of Smurf1.
Loading authentic research manuscript (Pages 1–5)...
Yuxin Chen, Xiao Tan, Meiling Lu, Yunfei Chen, Weijuan Pan, Rong Wei, Yingcong Wang (2026). PIPKI-PIP2 promotes cell migration by recruiting Smurf1 to the membrane and increasing its activity. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025217
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of PIP2 in Smurf1 membrane localization?
PIP2 binds to the C2 domain of Smurf1, which is essential for its recruitment to the plasma membrane. This membrane localization is critical for Smurf1's E3 ligase activity and its role in cell migration.
How does PIPKI regulate Smurf1 activity?
PIPKI generates PIP2, which in turn recruits Smurf1 to the membrane. This interaction enhances Smurf1's E3 ligase activity, thereby promoting cell migration.
What is the significance of the PIPKI-PIP2-Smurf1 axis?
The PIPKI-PIP2-Smurf1 signaling axis is a novel pathway that regulates cell migration. Understanding this axis could provide new therapeutic targets for cancer metastasis and other diseases involving abnormal cell migration.
Which domains of Smurf1 are involved in membrane binding?
The C2 domain of Smurf1 is responsible for binding to PIP2 and mediating membrane localization. This domain is also involved in substrate binding, linking membrane recruitment to substrate ubiquitination.
What are the potential clinical implications of this study?
Since cell migration is a key step in cancer metastasis, targeting the PIPKI-PIP2-Smurf1 axis could inhibit tumor invasion and spread. This study provides a molecular basis for developing drugs that disrupt this signaling pathway.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.